
    
      PRIMARY OBJECTIVES:

      I. To compare the Overall Survival (OS) for patients with Stage III unresectable non-small
      cell lung cancer treated with or without nivolumab following concurrent chemoradiation.

      II. To compare Progression-Free Survival (PFS) according to RECIST 1.1 criteria for patients
      with Stage III unresectable non-small cell lung cancer treated with or without nivolumab
      following concurrent chemoradiation.
    
  